

## **The CTSA Pharmaceutical Assets Portal and Partnership for Cures jointly support repurposing of the existing drugs**

The goal of the CTSA Pharmaceutical Assets Portal ([www.ctsapharmaportal.org](http://www.ctsapharmaportal.org)) is establishing collaborations between pharmaceutical companies and academic researchers in the area of drug repositioning, which means finding new uses for old drugs. The Portal is managed by the UC Davis Clinical and Translational Science Center on behalf of 46 CTSA universities around the U.S. The Portal also provides a critical link with NIH intramural scientists. The Portal serves as a focal point and a convener for development of the key provisions in the technology transfer.

The ultimate goal is to leverage existing compounds to advance mechanistic understanding of human disease, resulting in novel treatments for patients. Integration of academic investigators into collaborative repositioning efforts with pharmaceutical companies would substantially increase the knowledge base and the pool of methodologies available for proof-of-concept studies. These matches will undoubtedly result in an increased number of approved drugs for new indications and considerable public benefit. Membership in the Portal is free for CTSA researchers, and currently nearly 500 people are registered.

The mission of the **Partnership for Cures** ([www.4cures.org](http://www.4cures.org)) is to secure funds to improve healthcare outcomes and reduce patient healthcare costs worldwide by financing, facilitating, and publicizing Rediscovery Research solutions. These solutions include repurposing of existing drugs, testing clinical observations, and modifying treatment protocols. Partnership for Cures brings together a global collaboration of philanthropists, disease specific non-profits (VHOs), research institutions, researchers, patient support groups, industry, media and the lay public to create a multi-million dollar philanthropic fund that reuses and reconfigures existing medical and scientific knowledge from the literature and clinical practice to improve quality and length of life for patients.

### **How to become a Charter Partner:**

1. By joining the Initiative via an MOU (next page). There is no cost to join. The members gain the ability to submit Rediscovery Research grants.
2. By agreeing in writing that your organization believes that the Patient Impact Initiative can quickly, safely and economically improve quality and length of life for patients while they are still healthy enough to benefit.
3. By motivating your staff and faculty scientists, clinicians and lay members to develop and submit Rediscovery Research projects to the Patient Impact Initiative for review, approval and implementation.
4. By committing that if and when a Rediscovery Research™ grant from your institution is approved, the institution will co-fund 10% of the direct cost, with the remaining 90% coming from the Patient Impact Initiative.

Your institutional support of the Patient Impact Initiative is a key to generating new funding that will make a significant difference in the lives of patients, clinicians and scientists while reducing healthcare costs.

# MEMORANDUM OF UNDERSTANDING

## CONCERNING The Patient Impact Initiative

### BETWEEN

---

### AND Partnership for Cures

#### I. PURPOSE/OBJECTIVES/GOALS

This Memorandum of Understanding (MOU) sets in place mechanisms to create a new collaboration that utilize the complementary expertise and capabilities of the \_\_\_\_\_ and Partnership for Cures in the development, validation, and implementation of The Patient Impact Initiative utilizing Rediscovery Research™.

The central purpose of this MOU is to provide support and incentives for the advancement of Rediscovery Research™ that reuses, recombines and reapplies existing science and medicine to quickly, safely and affordably create “new” treatments for patients with catastrophic diseases.

Ultimately, the Rediscovery Research™ generated by this \_\_\_\_\_ and Partnership for Cures collaborations will create “new” treatments from old science and medicine that will improve quality and length of life for patients and reduce healthcare costs.

The goals of this MOU are to:

- (1) provide a program for \_\_\_\_\_ scientific and clinical staff to create Rediscovery Research™ projects that will become part of a Model Rediscovery Research™ Portfolio used to raise Rediscovery Research™ funding,
- (2) secure the support of \_\_\_\_\_ scientific and clinical staff in the creation of the Patient Impact Initiative grant program guidelines and
- (3) clarify the co-funding arrangement between the \_\_\_\_\_ and the Patient Impact Initiative for any \_\_\_\_\_ Rediscovery Research™ projects selected for funding.

#### II. BACKGROUND

Since 2005, Partnership for Cures, a Chicago based international 501(c)(3) public charity, has focused on raising funds for Rediscovery Research™. During that period researchers supported by these funds have created life saving or life changing Rediscovery Research™ treatments for children with deadly diseases ALPS and FD, and adults with multiple sclerosis, lung cancer, blood cancer and prostate cancer, and adult and children with type 1 diabetes. Each Rediscovery Research™ project that created these patient impacts had a total cost \$85,000-\$450,000, took an average of 28 months between project initiation and publication of results that could be used by practicing physicians and their patients, and reduced healthcare costs in excess of \$10,000/year per patient.

In 2010, Partnership for Cures was awarded a Social Entrepreneurship Fellowship by the Ashoka Foundation and its consulting partners to further develop the Rediscovery Research™ model.

Partnership for Cures and its consultants created the Patient Impact Initiative to provide the support for expanding the impact of Rediscovery Research™.

### III. ROLES AND RESPONSIBILITIES

Partnership for Cures will

- a) Provide the initial guidelines for the creation, internal review and submission of Rediscovery Research™ Projects (see Appendix A), which will be reviewed and improved by the input of Charter Research Institution partners.
- b) Provide those improved guidelines to the \_\_\_\_\_ in order for \_\_\_\_\_ clinicians and researchers to create mental health Rediscovery Research™ projects.
- c) Use those Rediscovery Research™ projects, and similar projects from other Charter Research Institution partners, to solicit research funding from a variety of sources.
- d) Create, with the assistance of Charter Research Institution partners, a Rediscovery Research™ Project grant review and selection process.
- e) Provide, through the Patient Impact Initiative, 90% of the funding for all selected Rediscovery Research™ project grants.
- f) Participate in the negotiation of any separate funding or other agreements involving Rediscovery Research™ projects selected for Patient Impact Initiative cooperative funding.
- g) Monitor all funded Patient Impact Initiative projects, providing quarterly reports to all funders, and support the publication of all Patient Impact Initiative Rediscovery Research™ results.

\_\_\_\_\_ will

- a) Promote the Patient Impact Initiative to \_\_\_\_\_ faculty, staff, patients and media contacts.
- b) Encourage participation by other research institutions, researchers, voluntary health organizations, industry, media and patient advocacy groups.
- c) Support the Patient Impact Initiative efforts to secure new funding for the Patient Impact Initiative from major philanthropies and other funders, which may, at the discretion of \_\_\_\_\_, include current \_\_\_\_\_ funders.
- d) Assist with the improvement of the Rediscovery Research™ Project submission process
- e) Motivate faculty and staff scientists, clinicians and lay members to develop and submit Rediscovery Research™ projects for review, approval and implementation.
- f) Assist with the creation of the Rediscovery Research™ Project grant submission review, ranking and selection process.
- g) Once one or more Rediscovery Research™ projects are approved that were submitted by \_\_\_\_\_, provide 10% of the cost of the projects, with the remaining 90% coming from general Patient Impact Initiative funding.
- h) Complete the approved and funded Rediscovery Research™ projects on time and on budget.
- i) Submit the results of the research for publication.

### IV. LIMITATIONS

All commitments made in this MOU are subject to the availability of appropriated funds and each party's current research and funding priorities. Nothing in this MOU, in and of itself, obligates any

participant to expend appropriations or to enter into any contract, assistance agreement, interagency agreement, or other financial obligation.

This MOU is neither a fiscal nor a funds obligation document. Any endeavor involving reimbursement or contribution of funds between the participants to this MOU will be handled in accordance with applicable laws, regulations, and procedures and will be subject to separate subsidiary agreements that will be effected in writing by representatives of the participants.

Except as provided in this Section, the Section LIMITATION and Section INTELLECTUAL PROPERTY, this MOU is not legally binding and does not create any right or benefit, substantive or procedural, enforceable by law or equity against the parties.

#### **V. INTELLECTUAL PROPERTY**

The parties agree that inventorship of any patentable matter, created by any of the participants pursuant to the terms of this MOU, will be determined in accordance with U.S. patent laws. Ownership will follow inventorship and vest in the inventors or their employers as determined by contract or law.

#### **VI. POINTS OF CONTACT**

The following individuals are designated points of contact for the MOU:

For Partnership for Cures:

Dr. Bruce E. Bloom  
President and Chief Science Officer  
70 West Madison Street, Suite 1500  
Chicago, IL 60602  
585-542-8737 (Direct)  
312-696-1366 (O)  
312-263-0939 (F)  
847-529-6888 (M)  
[Bruce@4cures.org](mailto:Bruce@4cures.org)

For \_\_\_\_\_

[name]  
[address]

#### **VII. MODIFICATION/DURATION/TERMINATION**

This MOU is to take effect upon signature of all participants and remain in effect for a period of \_\_\_\_\_ years, unless the participants decide otherwise in writing. This MOU may be amended at any time by the mutual written consent of the participants. Additionally, the participants agree to review this MOU annually to determine whether it should be revised, renewed, or cancelled. A participant may terminate its participation in this MOU by providing written notice to the other participants at least thirty (30) days in advance of the desired termination date.

**VIII. APPROVALS**

**For Partnership for Cures:**

\_\_\_\_\_  
**Dr. Bruce E. Bloom**  
**President and Chief Science Officer**

\_\_\_\_\_  
**Date**

**For \_\_\_\_\_:**

\_\_\_\_\_  
**Date**